entacingene turiparvovec (AAV-CNGB3) / J&J 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy:  Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) -  Jan 14, 2022   
    P1/2,  N=34, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=72 --> 34 | Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026
  • ||||||||||  entacingene turiparvovec (AAV-CNGB3) / J&J
    Trial primary completion date, Gene therapy:  Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) -  Jul 8, 2020   
    P1/2,  N=23, Completed, 
    Recruiting --> Active, not recruiting | N=72 --> 34 | Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026 Trial primary completion date: May 2019 --> Oct 2019
  • ||||||||||  entacingene turiparvovec (AAV-CNGB3) / J&J
    Trial completion, Gene therapy:  Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) -  Feb 5, 2020   
    P1/2,  N=23, Completed, 
    Trial primary completion date: May 2019 --> Oct 2019 Active, not recruiting --> Completed
  • ||||||||||  entacingene turiparvovec (AAV-CNGB3) / J&J
    Enrollment closed, Trial completion date, Trial primary completion date, Gene therapy:  Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) -  Sep 12, 2019   
    P1/2,  N=23, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Feb 2019 --> May 2019
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
    Enrollment change, Trial completion date, Trial primary completion date, Gene therapy:  Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) -  Sep 11, 2019   
    P1/2,  N=72, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Feb 2019 --> May 2019 N=18 --> 72 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  entacingene turiparvovec (AAV-CNGB3) / J&J
    New P1/2 trial, Gene therapy:  Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) -  Dec 19, 2017   
    P1/2,  N=18, Recruiting, 
  • ||||||||||  entacingene turiparvovec (AAV-CNGB3) / J&J
    Enrollment open, Gene therapy:  Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) -  Jan 25, 2017   
    P1/2,  N=18, Recruiting, 
    N=18 --> 72 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Jan 2016 | Not yet recruiting --> Recruiting